Skip to main
  1. Stocks
  2. Elevance Health Inc
  3. Forecast
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 35%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is favored because its 3Q26 outperformance and raised FY26 adjusted EPS guidance to at least $29.00 suggest stronger underlying earnings power, while management also reaffirmed at least 12% EPS growth in 2027. The company’s scale in employer, individual, and government-sponsored coverage, plus its unique Blue Cross Blue Shield position across 14 states and expanded Medicaid and Medicare Advantage footprint through acquisitions, supports durable membership depth and pricing leverage. Improving Medicaid margins from a trough-like 2026, at least 2% Medicare Advantage operating margin, stronger ACA retention, and Carelon’s growing contribution in PBM and services all point to a broadening, more resilient earnings mix.

Bears say

Elevance Health is pressured by material regulatory and underwriting risks that cloud earnings visibility, including about $669 million of IDR liabilities under the No Surprises Act and another $324 million of unresolved exposure, with 94% tied to ASO business and outcomes still dependent on regulatory and litigation developments. Its core government lines also face headwinds from Medicare Advantage reimbursement risk, Medicaid redeterminations, and potential ACA exchange deterioration, while PBM earnings from IngenioRx, which contribute about 20% of total company earnings, remain exposed to drug-pricing and transparency reforms. Compounding these issues, management has lowered target operating margins to 5.0%–6.0%, signaling weaker profitability as care trend uncertainty, slower membership growth, and integration risk from acquisitions weigh on fundamentals.

ELV has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 35% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

ELV Analyst Forecast & Price Prediction

Get the latest ELV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 20 analysts, ELV has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $458.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $458.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


ELV Analyst Forecast & Price Prediction

Get the latest ELV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ELV stock data and trends